Verdiva ends mid-stage study of oral GLP-1 amid ‘market evolution’

Phase 2negativeecnoglutide (oral)ecnoglutide (subcutaneous)Negative

AI Analysis

Summary

Verdiva has ended its mid-stage study of an oral GLP-1 candidate ecnoglutide, citing market evolution. Pfizer holds commercialization rights for the subcutaneous approved form in Asia.

Clinical Trial Data

Phase

Phase 2

Outcome Details

Study ended amid market evolution

Importance:5/10

Sentiment:

-0.60

GLP-1oral formulationtrial discontinuationweight managementtype 2 diabetes

Related Companies

$PFE

Read the original article

Published by BioSpace on October 14, 2026 12:27 PM

Read Original